Dayra Therapeutics is a newly launched biotechnology company pioneering a platform for discovering and optimizing oral macrocyclic peptides that selectively modulate disease-relevant proteins. Spun out of Versant Ventures’ Frontier Discovery Engine in 2024, the startup couples its proprietary macrocycle discovery capabilities with computational design and modeling. The initial focus is on high-value immunology targets, though the technology is applicable to additional therapeutic areas. Dayra’s team draws on deep macrocycle drug-development experience, and the company has already advanced molecules against several targets during its seed-stage work. A strategic collaboration with Biogen will supply validation, development, and commercialization capabilities, while giving Biogen an option to acquire resulting candidates. The company has secured more than $70 million in committed funding, providing a multi-year runway to progress its pipeline toward preclinical and clinical milestones.

Total raised

$70M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025